

STORAGE INSTRUCTIONS

Store all reagents at 2-8°C in an upright position when not in use. Do not freeze reagents. Pipets and slides do not require refrigeration.

INDICATIONS OF DETERIORATION

1. Turbidity or precipitation in controls is indicative of deterioration and the component should not be used.
2. Bacterial contamination of reagents or specimens may cause false positive results.

SPECIMEN COLLECTION AND STORAGE

1. Use only serum that is free from contamination. Test samples should not be heat-inactivated.
2. It is preferable to test samples on the day of their collection. If samples cannot be tested immediately, maintain them in their original tubes at 2-8°C and test within 48 hours.
3. Serum samples stored longer than 48 hours should be stored at -20°C or below until testing. Avoid repeated freezing and thawing of specimens.
4. If necessary before testing, centrifuge the specimens at a force sufficient to sediment cellular components.
5. Samples to be sent out for testing should be placed on ice packs and packaged like any other biohazardous material that could potentially transmit infection.

PERFORMANCE OF THE TEST

Materials Provided:

	25 Tests	50 Tests	100 Tests	1000 Tests
ASO LATEX REAGENT	1.0 ml	2.0 ml	2 x 2.0 ml	20 x 2.0 ml
REACTIVE CONTROL	0.5 ml	1.0 ml	1.0 ml	10 x 1.0 ml
NONREACTIVE CONTROL	0.5 ml	1.0 ml	1.0 ml	10 x 1.0 ml
0.03 ml Disposable Stirrer Pipets	25	50	100	1000
Disposable Test Cards (6-well)	5	9	17	170

ADDITIONAL MATERIALS REQUIRED

- Timing device
- 13 x 75 mm test tubes
- Volumetric pipet to deliver 0.25 ml
- Saline (0.9% NaCl solution)
- Mechanical rotator (optional)

TEST PROCEDURE

PREPARATION FOR THE ASSAY

1. Allow all reagents and samples to warm to room temperature (20-30°C) before use. Remove reagents from foam holders. Do not heat reagents in a water bath.
2. All reagents are ready for use as supplied. Gently mix the reagents before use; avoid foaming.
3. Gently mix the LATEX REAGENT before each use to ensure homogeneity.

ASSAY PROTOCOL- QUALITATIVE

1. Using the stirrer pipets, deliver one free-falling drop (0.03 ml) of each serum sample onto a separate circle on the test card. Use a fresh stirrer pipet for each sample. When using the stirrer pipet, keep it in a vertical position to ensure accurate delivery. Repeat by adding one free-falling drop of REACTIVE or NONREACTIVE CONTROL from the dropper vials supplied. Note the location of each sample by using the numbers located below and to the left of each circle.
2. Expel the contents of the LATEX REAGENT dropper and refill. Add one drop of the reagent to each serum specimen and to each control.
3. Using the flat end of the stirrer pipets, mix each specimen and control serum with the LATEX REAGENT, in a circular manner, over the entire area in the circles of the card.
4. Gently tilt and rotate the card for two (2) minutes and observe for agglutination. All test results should be compared to both REACTIVE and NONREACTIVE CONTROLS.

ASSAY PROTOCOL- SEMIQUANTITATIVE

1. Prepare serial dilutions of patient serum in SALINE SOLUTION in test tubes as follows:

Tube	Dilution	Composition
1	1:2	0.25 ml of serum + 0.25 ml of saline solution. Mix.
2	1:4	0.25 ml from tube 1 + 0.25 ml of saline solution. Mix.
3	1:8	0.25 ml from tube 2 + 0.25 ml of saline solution. Mix.
4	1:16	0.25 ml from tube 3 + 0.25 ml of saline solution. Mix.
5	1:32	0.25 ml from tube 4 + 0.25 ml of saline solution. Mix.

Testing on additional dilutions should be performed as needed.

- Using each dilution as a separate test specimen, apply the samples to the card as described in step 1 of the Qualitative Assay Protocol and proceed with steps 2 through 4 of the Qualitative Assay Protocol. Include undiluted sample if not tested previously on that day with the same lot of LATEX REAGENT.

QUALITY CONTROL

Quality Control requirements must be performed in accordance with applicable local, state and/or federal regulations or accreditation requirements and your laboratory's standard Quality Control Procedures. Controls with graded reactivity should be included. If control samples do not yield the expected response, the assay should be considered invalid and the assay repeated. If the repeat assay does not elicit the expected results for the control samples, discontinue use of the kit and contact ASI Technical Support at (800) 654-0146.

INTERPRETATION OF RESULTS- QUALITATIVE

Agglutination indicates an ASO concentration of greater than or equal to 200 IU/ml in the serum sample. Sera that elicit a positive result should be retested and titered using the Semiquantitative Assay Protocol.

INTERPRETATION OF RESULTS- SEMIQUANTITATIVE

The highest dilution in which visible agglutination occurs is considered the endpoint titer. The corresponding ASO concentration (in IU/ml) is calculated as the product of the endpoint dilution factor and the assay cut-off value as shown in the following table. For example, if the endpoint dilution is 1:8, the corresponding ASO serum concentration would be 8 x 200, or 1600 IU/ml.

Dilution	ASO IU/ml (in NEAT specimen)
NEAT*	200
1:2	400
1:4	800
1:8	1600
1:16	3200
1:32	6400

*NEAT = undiluted

LIMITATIONS OF THE PROCEDURE

- Because extremely high levels of antibodies might affect the degree of agglutination, positive samples should be reassayed using the semiquantitative procedure.
- Contaminated, lipemic, or grossly hemolyzed sera should not be used because of the possibility of nonspecific results.
- Plasma samples should not be used because of the possibility of nonspecific results.
- Temperature of the reagents and samples is crucial to test outcome. It should be between 20° and 30°C.
- Reaction times longer than specified might cause false positive results due to a drying effect.
- Elevated serum levels of beta-lipoprotein and cholesterol might suppress a rise in ASO titer.
- Penicillin or other antibiotic therapy might suppress a rise in ASO titer.
- In accord with all diagnostic methods, a final diagnosis should not be made on the result of a single test, but should be based on a correlation of test results with other clinical findings.

EXPECTED VALUES

It is common to detect ASO antibodies in most of the population with titers varying according to geographical location and age distribution. Increased ASO titers may be associated with rheumatic fever and glomerulonephritis.³ An ASO titer of more than 200 IU/ml might be indicative of streptococcal infection. The titer should be monitored over a time period of 4 to 6 weeks.

REFERENCES

1. Halbert SP. 1963. *Ann NY Acad Sci*, **103**:1027-1051.
2. Klein GL. 1971. *App Microbiol*, **21**:999.
3. Klein GC. 1976. *Manual of Clinical Immunology*, American Society for Microbiology, Washington DC, p. 264.



MedEnvoy Global B.V.

Prinses Margrietplantsoen 33 - Suite 123
2595 AM The Hague
The Netherlands

ARLINGTON
SCIENTIFIC

(800) 654-0146 (801) 489-8911
1840 N Technology Drive, Springville, UT, 84663 USA
Fax (801) 489-5552 info@arlingtonscientific.com
www.arlingtonscientific.com